Mar. 26 at 9:08 AM
$FBIO Fortress Biotech – Assets/Sum of parts - Part 8A
3. Subsidiaries without significant value today that should only be valued as a future bonus
Mustang
$MBIO – 12% (probably lower today), 4.5% Royalty, 2.5% Annual Equity Dividend
Avenue
$ATXI - 14% (probably lower today), 4.5% Royalty, 2.5% Annual Equity Dividend
Cellvation – 79.2%, 4.5% Royalty, 2.5% Annual Equity Dividend
Oncogenuity – 73,5%, 4.5% Royalty, 2.5% Annual Equity Dividend
Aevitas – (Sold)
Eligible to ~
$140M in potential late-stage development for 4D-175, regulatory and sales milestone payments plus royalties from
$FDMT
From Q4 2024 (28/2-2025):
“Paused significant additional capital allocation and investment, pending additional financing or partnerships for the following therapeutics:
4D-175 for geographic atrophy
… “